Long‑Term Safety and Management of Intranasal Corticosteroids in Adults

Systemic Safety Profile

Intranasal corticosteroids administered at standard, recommended doses do not produce clinically significant systemic adverse effects in adult patients. 1
No hypothalamic‑pituitary‑adrenal (HPA) axis suppression has been observed with any intranasal corticosteroid formulation when used at approved dosing. 1
Standard‑dose therapy does not increase the risk of glaucoma in adult users. 2
Prospective 24‑week trials found no association between intranasal corticosteroid use and the development of cataracts. 2
Long‑term use at approved doses shows minimal impact on bone mineral density, with studies reporting no significant loss of bone mass. 3

Epistaxis occurs in roughly 5–10 % of adult users; episodes are generally mild and present as blood‑tinged nasal secretions. 1
Nasal irritation, burning, or stinging may be experienced, especially with formulations containing propylene glycol. 2
A bitter taste is a characteristic side effect of azelastine‑containing products such as Ryaltris. 4
Nasal septal perforation is a rare event with long‑term intranasal corticosteroid therapy. 2
Mucosal erosions can precede perforation but are uncommon; when present they warrant closer monitoring. 3

Directing the spray laterally toward the outer nasal wall (away from the septum) reduces the risk of mucosal erosion and perforation. 1
Performing a periodic nasal examination (every 6–12 months) allows early detection of mucosal changes that could signal increased perforation risk. 2
Using the lowest effective dose that adequately controls allergic rhinitis symptoms optimizes safety while maintaining efficacy. 1
Proper spray technique—aiming laterally and avoiding the septum—is recommended for all intranasal corticosteroid products. 1
Concurrent use of topical nasal decongestants should be limited to no more than 3 days to prevent rhinitis medicamentosa. 1

Adults may continue intranasal corticosteroid therapy indefinitely at recommended doses; no maximum duration is stipulated by regulatory labeling. 1
Clinical practice guidelines endorse continuous use as the most effective strategy for managing persistent allergic rhinitis. 4
Treatment should be maintained as long as allergen exposure persists, with the option to pause and restart for seasonal symptom patterns. 4

Histologic evaluation of nasal mucosa after 1–5 years of therapy shows no evidence of atrophy, ulceration, or other pathological changes. 2

All bullet points are supported by the cited references indicated in brackets.

The American Academy of Otolaryngology–Head and Neck Surgery lists multiple FDA‑approved intranasal corticosteroid sprays for allergic rhinitis, including first‑generation agents (beclomethasone dipropionate, budesonide, triamcinolone acetonide, flunisolide) and second‑generation agents (fluticasone propionate, fluticasone furoate, mometasone furoate, ciclesonide), each with specific age approvals and over‑the‑counter or prescription status【5】.

According to the American Academy of Allergy, Asthma & Immunology, all intranasal corticosteroids provide comparable efficacy at recommended doses and represent the most effective monotherapy for controlling sneezing, itching, rhinorrhea, and nasal congestion in allergic rhinitis【6】【7】【8】.
Comparative trials show no significant difference in clinical response among the currently available intranasal corticosteroid formulations【8】.

Therapeutic benefit typically begins within 12 hours of the first dose, with some patients experiencing relief as early as 3–4 hours【9】【8】.
Full symptom control may require several days to weeks of continuous daily use【10】.

When used at recommended doses, intranasal corticosteroids are not associated with clinically significant systemic adverse effects in adult patients【11】【12】.
In pediatric patients, higher‑dose beclomethasone dipropionate may affect growth, whereas fluticasone propionate, mometasone furoate, and budesonide have not demonstrated growth suppression at standard doses【12】【13】.

The most common local side effects are nasal irritation, epistaxis (occurring in approximately 5–10 % of users), burning, stinging, and headache【11】.
Proper spray technique—aiming away from the nasal septum—reduces the risk of mucosal erosion and rare septal perforation【11】【12】.